Upadacitinib
Treatment for Eczema
Typical Dosage: 15-30 mg orally once daily
Effectiveness
92%
Safety Score
45%
Clinical Trials
36
Participants
5.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
15-30 mg orally once daily
Time to Effect
1-2 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$42,000
Monitoring:$700
Side Effect Mgmt:$200
Total Annual:$42,900
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$63,088
Cost per Remission
$143,000
Comparison vs Dupilumab
Cost Difference
+$1,000/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Upadacitinib Outcomes
for Eczema
Efficacy Outcomes
Overall Effectiveness
+92%
Response Rate
+68%
Remission Rate
+30%
Common Side Effects
Upper respiratory tract infections
+15%
Acne
+8%
Headache
+7%
Herpes zoster
+3%
Elevated creatine phosphokinase
+6%
Serious infections (including pneumonia)
+1%
Major adverse cardiovascular events (MACE)
+0.5%
Venous thromboembolism (VTE)
+0.5%
Malignancy
+0.3%
Active Clinical Trials
7 active trials recruiting for Upadacitinib in Eczema
Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis
NCT06701331RECRUITINGPHASE3
98 participants
INTERVENTIONAL
Nagoya, Japan +24 more
Started: Dec 22, 2024
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897RECRUITINGPHASE3
675 participants
INTERVENTIONAL
Little Rock, United States +144 more
Started: Aug 19, 2024
Replication of the Heads Up Atopic Dermatitis Trial With Registry Data
NCT06937788RECRUITING
240 participants
OBSERVATIONAL
Dresden, Germany
Started: Aug 2, 2021
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
NCT06389136RECRUITINGPHASE3
200 participants
INTERVENTIONAL
Fayetteville, United States +101 more
Started: Jun 12, 2024
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318ACTIVE NOT RECRUITINGPHASE3
1.53K participants
INTERVENTIONAL
Birmingham, United States +192 more
Started: Aug 9, 2018
Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models
NCT06366932RECRUITINGPHASE4
150 participants
INTERVENTIONAL
Madrid, Spain
Started: Sep 25, 2023
Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)
NCT06498167RECRUITING
150 participants
OBSERVATIONAL
Porto, Portugal +2 more
Started: Jul 1, 2024
Completed Clinical Trials
10 completed trials for Upadacitinib in Eczema
Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT04195698COMPLETEDPHASE3
475 participants
INTERVENTIONAL
Little Rock, United States +115 more
Started: Jan 15, 2020
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
NCT03569293COMPLETEDPHASE3
912 participants
INTERVENTIONAL
Phoenix, United States +179 more
Started: Aug 13, 2018
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05507580COMPLETEDPHASE4
461 participants
INTERVENTIONAL
Darlinghurst, Australia +105 more
Started: May 29, 2023
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
NCT03607422COMPLETEDPHASE3
912 participants
INTERVENTIONAL
Birmingham, United States +195 more
Started: Jul 27, 2018
Real-world Experience on the Use of Upadacitinib in the Treatment of Moderate-severe Adult Atopic Dermatitis (ERUDA)
NCT05989932COMPLETED
146 participants
OBSERVATIONAL
Roma, Italy
Started: Dec 15, 2021
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis
NCT03646604COMPLETEDPHASE1
35 participants
INTERVENTIONAL
Huntington Beach, United States +17 more
Started: Jan 31, 2019
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05601882COMPLETEDPHASE3
920 participants
INTERVENTIONAL
Phoenix, United States +256 more
Started: Nov 28, 2022
A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis
NCT02925117COMPLETEDPHASE2
167 participants
INTERVENTIONAL
Tampa, United States +33 more
Started: Oct 25, 2016
A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03661138COMPLETEDPHASE3
272 participants
INTERVENTIONAL
Ichinomiya-shi, Japan +42 more
Started: Oct 27, 2018
A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03738397COMPLETEDPHASE3
673 participants
INTERVENTIONAL
Birmingham, United States +158 more
Started: Feb 21, 2019
Showing 20 of 36 total trials